Back to Feed
ClinicalTrials.gov|Clinical Trial
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
Abstract
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL); Transformed Follicular Lymphoma (tFL); Follicular Lymphoma Grade 3B; DLBCL; DLBCL - Diffuse Large B Cell Lymphoma; DLBCL Arising From Follicular Lymphoma; DLBCL, Diffused Large B Cell Lymphoma; DLBCL NOS Interventions: P-CD19CD20-ALLO1; Rimiducid
Keywords
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh-grade B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Transformed Follicular Lymphoma (tFL)Follicular Lymphoma Grade 3BDLBCLDLBCL - Diffuse Large B Cell LymphomaDLBCL Arising From Follicular LymphomaDLBCL, Diffused Large B Cell LymphomaDLBCL NOS